CD91 on dendritic cells governs immunosurveillance of nascent, emerging tumors.
Level 5 - mechanism / opinion, no new human data
Preclinical mechanistic bench/animal study with correlative human polymorphism data
PubMed 30944251 · doi:10.1172/jci.insight.127239
What was done
The authors investigated the role of CD91, a receptor on antigen-presenting cells, in priming immune responses to nascent, emerging tumors in experimental models and evaluated the relationship between human CD91 ligand-binding polymorphisms and antitumor immune responses in cancer patients.
What was found
The abstract reports no numerical data, effect estimates, or sample sizes. Qualitatively, absence of CD91 resulted in subdued effector immune responses and increased tumor incidence and progression, tumors developing without CD91 exhibited neo-epitopes indicative of greater immunogenicity, and human CD91 polymorphisms affected antitumor immune responses.
Why it matters
The study outlines a molecular mechanism where dendritic cell CD91 mediates early tumor immunosurveillance, pointing to potential genetic variation influencing cancer susceptibility and progression.
Limits
The abstract provides no sample sizes, specific cancer types, quantitative metrics, or detailed clinical characteristics. The evidence is predominantly preclinical and mechanistic with unspecified observational human genetic associations.
Cited by
- supports The human immune system actively identifies and eliminates emerging cancer cells on a daily basis.